3 ms·

Nope. Moderna's share price and general outlook has flatlined at its pre-2020 levels a long time ago. They have no products, they aren't well capitalized and th

Nope. Moderna's share price and general outlook has flatlined at its pre-2020 levels a long time ago. They have no products, they aren't well capitalized and they might liquidate at some point. This vaccine was a no-hoper like all other Moderna's products. That's why the article says: "Shares of Moderna were flat in after-market trading." The smart money wasn't surprised because this was never going to make it to market. Although this will be interpreted on the left as a partisan move (with the administration lying under duress or something), it's likely that they're telling the truth about why it was cancelled. Trump after all was a big supporter of the Moderna vaccines. But mRNA tech just doesn't work when normal safety standards are re-imposed. I wrote about the problem here a couple of weeks ago: https://news.ycombinator.com/item?id=44003338 https://news.ycombinator.com/item?id=44003338 It's easy to forget that the COVID vaccines were an emergency measure. The way they were judged wasn't how pharma products are normally judged.

Izkata 1y ago
On the lipid nanoparticle toxicity, I remember an article from either 2020 or 2021 that claimed they had some sort of breakthrough in 2019 that reduced the toxicity, though didn't solve it completely. Unfortunately I don't remember the details and hadn't been able to find it again when I tried a year or two afterwards.
- mike_hearn 1y ago
  I looked for such a breakthrough at the time and could find no evidence of such a thing. They also claimed in 2020 that mRNA was some sort of easily programmable bio-software that would let them launch new vaccines within weeks, but that didn't happen either.
leoh 1y ago
They currently have a market cap of $10B.
- Aloisius 1y ago
  What does that have to do with well capitalized a company is? It looks like Moderna have enough capital available to meet their obligations for a while, but they do appear to be burning through it.
- mike_hearn 1y ago
  They have a hangover of funds from the COVID times but not much income or investor interest compared to their burn rate.

Izkata 1y ago

On the lipid nanoparticle toxicity, I remember an article from either 2020 or 2021 that claimed they had some sort of breakthrough in 2019 that reduced the toxicity, though didn't solve it completely. Unfortunately I don't remember the details and hadn't been able to find it again when I tried a year or two afterwards.

mike_hearn 1y ago
I looked for such a breakthrough at the time and could find no evidence of such a thing. They also claimed in 2020 that mRNA was some sort of easily programmable bio-software that would let them launch new vaccines within weeks, but that didn't happen either.

leoh 1y ago

They currently have a market cap of $10B.

Aloisius 1y ago
What does that have to do with well capitalized a company is? It looks like Moderna have enough capital available to meet their obligations for a while, but they do appear to be burning through it.
mike_hearn 1y ago
They have a hangover of funds from the COVID times but not much income or investor interest compared to their burn rate.